An editorial in this morning’s Yomiuri Shimbun reminded me of a mind-blowing conversation I had the other day with an accomplished health care investor. Today’s Yomiuri editorial, Extremely high drug prices should be reviewed for appropriateness, cites the case of Kymriah, a breakthrough biological drug which efficaciously treats certain types of leukemia and other blood […]